Emergent Biosolutions Stock Debt To Equity
| EBS Stock | USD 5.88 0.19 3.13% |
Fundamental analysis of Emergent Biosolutions allows traders to better anticipate movements in Emergent Biosolutions' stock price by examining its financial health and performance throughout various phases of its business cycle.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Emergent Biosolutions Company Debt To Equity Analysis
Emergent Biosolutions' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Emergent Biosolutions Debt To Equity | 0.56 % |
Most of Emergent Biosolutions' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Emergent Biosolutions is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, Emergent Biosolutions has a Debt To Equity of 0.563%. This is 98.95% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The debt to equity for all United States stocks is 98.84% higher than that of the company.
Emergent Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Emergent Biosolutions' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Emergent Biosolutions could also be used in its relative valuation, which is a method of valuing Emergent Biosolutions by comparing valuation metrics of similar companies.Emergent Biosolutions is currently under evaluation in debt to equity category among its peers.
Emergent Fundamentals
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.0161 | ||||
| Profit Margin | (0.14) % | ||||
| Operating Margin | 0.23 % | ||||
| Current Valuation | 846.07 M | ||||
| Shares Outstanding | 54.28 M | ||||
| Shares Owned By Insiders | 2.82 % | ||||
| Shares Owned By Institutions | 67.00 % | ||||
| Number Of Shares Shorted | 9.06 M | ||||
| Price To Earning | 1.67 X | ||||
| Price To Book | 0.60 X | ||||
| Price To Sales | 0.34 X | ||||
| Revenue | 1.01 B | ||||
| Gross Profit | 354 M | ||||
| EBITDA | 36.9 M | ||||
| Net Income | (190.6 M) | ||||
| Cash And Equivalents | 99.5 M | ||||
| Cash Per Share | 7.28 X | ||||
| Total Debt | 663.7 M | ||||
| Debt To Equity | 0.56 % | ||||
| Current Ratio | 3.92 X | ||||
| Book Value Per Share | 10.14 X | ||||
| Cash Flow From Operations | 58.7 M | ||||
| Short Ratio | 6.12 X | ||||
| Earnings Per Share | (2.58) X | ||||
| Price To Earnings To Growth | 1.55 X | ||||
| Target Price | 13.5 | ||||
| Number Of Employees | 900 | ||||
| Beta | 2.09 | ||||
| Market Capitalization | 329.47 M | ||||
| Total Asset | 1.39 B | ||||
| Retained Earnings | (212.4 M) | ||||
| Working Capital | 436.3 M | ||||
| Current Asset | 537.41 M | ||||
| Current Liabilities | 99.61 M | ||||
| Net Asset | 1.39 B |
About Emergent Biosolutions Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Emergent Biosolutions's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Emergent Biosolutions using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Emergent Biosolutions based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Emergent Stock Analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.